dalteparin has been researched along with B16 Melanoma in 7 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental metastasis of B16F10-VLA-4kd and B16F10 cells and interference by Tinzaparin were analysed in mice." | 1.40 | The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. ( Bendas, G; Borsig, L; Naggi, A; Ortmann, K; Roblek, M; Schlesinger, M; Torri, G, 2014) |
| "Using the B16 melanoma mouse model of metastasis, subcutaneous (s." | 1.33 | Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. ( Amirkhosravi, A; Francis, JL; Linhardt, R; Mousa, SA, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Debergh, I | 1 |
| Van Damme, N | 1 |
| Pattyn, P | 1 |
| Peeters, M | 1 |
| Ceelen, WP | 1 |
| Ludwig, RJ | 1 |
| Alban, S | 1 |
| Bistrian, R | 1 |
| Boehncke, WH | 1 |
| Kaufmann, R | 1 |
| Henschler, R | 1 |
| Gille, J | 1 |
| Mousa, SA | 2 |
| Linhardt, R | 1 |
| Francis, JL | 2 |
| Amirkhosravi, A | 2 |
| Schlesinger, M | 1 |
| Roblek, M | 1 |
| Ortmann, K | 1 |
| Naggi, A | 1 |
| Torri, G | 1 |
| Borsig, L | 1 |
| Bendas, G | 1 |
| Goertz, L | 1 |
| Schneider, SW | 1 |
| Desch, A | 1 |
| Mayer, FT | 1 |
| Koett, J | 1 |
| Nowak, K | 1 |
| Karampinis, I | 1 |
| Bohlmann, MK | 1 |
| Umansky, V | 1 |
| Bauer, AT | 1 |
| Amaya, M | 1 |
| Kragh, M | 1 |
| Binderup, L | 1 |
| Vig Hjarnaa, PJ | 1 |
| Bramm, E | 1 |
| Johansen, KB | 1 |
| Frimundt Petersen, C | 1 |
7 other studies available for dalteparin and B16 Melanoma
| Article | Year |
|---|---|
The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.
Topics: Animals; Anticoagulants; Blood Flow Velocity; Cricetinae; Erythrocytes; Immunoenzyme Techniques; Mel | 2010 |
The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose | 2006 |
Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Cell Line, Tumor; Dose-Response R | 2006 |
The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Topics: Animals; Anticoagulants; Cell Adhesion; Cell Line, Tumor; Cell Movement; Heparin, Low-Molecular-Weig | 2014 |
Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.
Topics: Animals; Blood Vessels; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Factor Xa Inhibitors; | 2016 |
Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Topics: Animals; Endothelium, Vascular; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Lipoprot | 2003 |
Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth.
Topics: Animals; Anticoagulants; Carbohydrate Sequence; Cell Line, Tumor; Female; Heparin, Low-Molecular-Wei | 2005 |